Literature DB >> 3689636

Apparently normal phenytoin metabolism in a patient with phenytoin-induced rash and lymphadenopathy.

J H Maguire1, G Wettrell, A Rane.   

Abstract

A 10-year old female on phenytoin therapy developed a rash and lymphadenopathy. H.p.l.c. assays of urinary metabolites indicated no differences in stereoselective metabolism of phenytoin to phenolic and dihydrodiol metabolites as compared with volunteers given the drug or with pediatric patients without adverse reactions. This suggests that no obvious difference in stereoselective metabolism of phenytoin to potentially toxic arene oxides exists between this patient and other patients on phenytoin. Our results are consistent with the hypothesis that differences in peripheral detoxication of phenytoin arene oxides and not differences in hepatic metabolism of phenytoin may be responsible for such adverse reactions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3689636      PMCID: PMC1386321          DOI: 10.1111/j.1365-2125.1987.tb03212.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Phenytoin teratogenesis: correlation between embryopathic effect and covalent binding of putative arene oxide metabolite in gestational tissue.

Authors:  F Martz; C Failinger; D A Blake
Journal:  J Pharmacol Exp Ther       Date:  1977-10       Impact factor: 4.030

2.  Gas chromatographic on-column methylation technique for the simulataneous determination of antiepileptic drugs in blood.

Authors:  K H Dudley; D L Bius; B L Kraus; L W Boyles
Journal:  Epilepsia       Date:  1977-06       Impact factor: 5.864

3.  High-performance liquid chromatographic determination of the enantiomeric composition of urinary phenolic metabolites of phenytoin.

Authors:  J S McClanahan; J H Maguire
Journal:  J Chromatogr       Date:  1986-09-05

4.  Arene oxides: a new aspect of drug metabolism.

Authors:  D M Jerina; J W Daly
Journal:  Science       Date:  1974-08-16       Impact factor: 47.728

5.  Characterization of soluble glutathione transferase activity in resting mononuclear leukocytes from human blood.

Authors:  J Seidegård; J W De Pierre; W Birberg; A Pilotti; R W Pero
Journal:  Biochem Pharmacol       Date:  1984-10-01       Impact factor: 5.858

6.  Hereditary interindividual differences in the glutathione transferase activity towards trans-stilbene oxide in resting human mononuclear leukocytes are due to a particular isozyme(s).

Authors:  J Seidegård; J W DePierre; R W Pero
Journal:  Carcinogenesis       Date:  1985-08       Impact factor: 4.944

7.  Measurement and characterization of membrane-bound and soluble epoxide hydrolase activities in resting mononuclear leukocytes from human blood.

Authors:  J Seidegård; J W DePierre; R W Pero
Journal:  Cancer Res       Date:  1984-09       Impact factor: 12.701

8.  Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro.

Authors:  W T Gerson; D G Fine; S P Spielberg; L L Sensenbrenner
Journal:  Blood       Date:  1983-05       Impact factor: 22.113

9.  Anticonvulsant toxicity in vitro: possible role of arene oxides.

Authors:  S P Spielberg; G B Gordon; D A Blake; E D Mellits; D S Bross
Journal:  J Pharmacol Exp Ther       Date:  1981-05       Impact factor: 4.030

10.  Determination of 5-(3,4-Dihydroxy-1,5-cyclohexadien-1-yl)-5-phenylhydantoin (Dihydrodiol) and quantitative studies of phenytoin metabolism in man.

Authors:  J H Maguire; B L Kraus; T C Butler; K H Dudley
Journal:  Ther Drug Monit       Date:  1979       Impact factor: 3.681

View more
  2 in total

Review 1.  Immunological adverse effects of anticonvulsants. What is their clinical relevance?

Authors:  F De Ponti; S Lecchini; M Cosentino; C M Castelletti; A Malesci; G M Frigo
Journal:  Drug Saf       Date:  1993-03       Impact factor: 5.606

Review 2.  Drug-induced skin, nail and hair disorders.

Authors:  Laurence Valeyrie-Allanore; Bruno Sassolas; Jean-Claude Roujeau
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.